Shares of Iovance Biotherapeutics (NASDAQ: IOVA) popped 18.7% on Thursday as investors assessed the fallout of a clinical hold placed on a cancer-therapy trial yesterday by the U.S. Food and Drug Administration (FDA).
A setback for a much-needed treatment
Today’s rebound nearly recouped an almost 20% drop yesterday for Iovance, which came on the heels of a U.S. Food and Drug Administration (FDA) decision to place a clinical hold on its IOV-LUN-202 clinical trial following a patient’s death. The trial was evaluating Iovance’s LN-145 TIL experimental therapy to treat non-small-cell lung cancer (NSCLC).
Iovance issued a press release explaining that the death was “potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen” of the trial. At the same time, Iovance pointed out the dire need for therapies in cases such as these, noting that the patients in the trial “have a poor prognosis, limited treatment options, and a real-world overall survival of less than six months.”
What’s next for Iovance investors?
In any case, Iovance has paused enrollment in the treatment regimen for new patients during the clinical hold, and it will continue to monitor and follow patients previously treated according to the trial protocol. The company says patients who have already undergone tumor resection will continue to receive the LN-145 TIL treatment regimen “with additional precautions and risk mitigations.”
Of note from an investor’s standpoint (and potentially contributing to today’s rebound): LN-145 TIL isn’t Iovance’s lead drug candidate. Rather, more important to the company’s near-term survival is its lifileucel advanced melanoma treatment, which could generate peak annual sales of as much as $900 million and for which the company expects to receive an FDA-approval decision by Feb. 24, 2024.
The potential approval of lifileucel is unrelated to LN-145 TIL’s clinical trial. That’s a potentially massive revenue stream for a company whose entire market cap sits at just $2.2 billion today. And opportunistic shareholders appear to be taking advantage of yesterday’s drop to invest accordingly.
Should you invest $1,000 in Iovance Biotherapeutics right now?
Before you buy stock in Iovance Biotherapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Iovance Biotherapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of December 18, 2023
Steve Symington has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy.
Why Iovance Biotherapeutics Stock Popped Today was originally published by The Motley Fool
Jessica Roberts is a seasoned business writer who deciphers the intricacies of the corporate world. With a focus on finance and entrepreneurship, she provides readers with valuable insights into market trends, startup innovations, and economic developments.
